Welcome to our dedicated page for Aprea Therapeutics SEC filings (Ticker: APRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aprea Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage oncology company developing targeted therapies for biomarker-defined cancers. Its Form 8-K disclosures cover material events such as clinical updates for APR-1051, operating and financial results, corporate presentation updates, private-placement financing, capital-structure information, and Nasdaq listing-compliance notices.
Proxy materials for Aprea address annual meeting procedures and shareholder voting matters. The filing record also identifies the company’s common stock under the symbol APRE and provides formal disclosures tied to governance, financing activity, public-company reporting obligations, and the development status of its precision medicine oncology programs.
Aprea Therapeutics president and CEO Gilad Oren reported new equity awards. He received stock options for 80,700 shares of common stock at an exercise price of $0.765 per share, expiring on March 12, 2036. These options vest 25% on March 12, 2027, with the remainder vesting ratably over the following 36 months, subject to continued employment.
Oren was also granted 20,175 restricted stock units that vest in three equal annual installments beginning on March 12, 2027, also subject to continued employment. Following these grants, he directly holds 393,895 shares of common stock. Additional indirect holdings of 1,200 and 600 shares are reported for his daughter and son, with beneficial ownership disclaimed.
Aprea Therapeutics reported that SrVP/CFO/Principal Financial and Accounting Officer John P. Hamill received new equity compensation. He was granted 40,380 stock options with an exercise price of $0.765 per share, expiring on March 12, 2036.
Twenty-five percent of these options vest on March 12, 2027, with the remainder vesting monthly over the following 36 months, contingent on continued employment. Hamill also received 10,095 restricted stock units, vesting in three equal annual installments starting March 12, 2027. Following the RSU grant, his common stock holdings total 43,528 shares.
Aprea Therapeutics, Inc. reported fourth quarter and full-year 2025 results and provided a corporate update. For 2025, grant revenue was $285,759, down from $1,502,581 in 2024, reflecting lower non-dilutive funding.
Total operating expenses for 2025 were $13,519,595, compared with $15,822,236 in 2024, driven by lower research and development spending of $7,043,035 and relatively stable general and administrative costs of $6,476,560. Net loss for 2025 was $12,599,569, slightly improved from $12,958,711 in 2024, with net loss per share narrowing to $1.93 from $2.35.
On the balance sheet, total assets at December 31, 2025 were $15,933,401, down from $23,979,493 a year earlier, including cash and cash equivalents of $14,599,347. The company highlighted progress in its WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119 programs and noted recent private placements that strengthened its balance sheet, while emphasizing its focus on targeted therapies for biomarker-defined cancers.
Aprea Therapeutics registers 12,577,714 shares for resale by private placement investors. This registration covers up to 12,577,714 shares of Common Stock consisting of 1,877,677 shares issued in the January 30, 2026 private placement, 4,411,180 shares issuable upon exercise of pre-funded warrants, and 6,288,857 shares issuable upon exercise of common warrants.
The company is not offering any shares for its own account and will not receive proceeds from resales, although it will receive proceeds from any cash exercise of warrants. The filing discloses an exercise price of $0.765 for common warrants and $0.001 for pre-funded warrants, and states the company had 11,451,118 shares outstanding as of January 30, 2026. The last reported Nasdaq sale price was $0.8179 on February 19, 2026.
Aprea Therapeutics reported new early clinical signals for its WEE1 inhibitor APR-1051 from the ongoing Phase 1 ACESOT-1051 trial in advanced solid tumors. A second unconfirmed partial response was seen in a patient with advanced endometrial cancer at the 220 mg dose, showing a 50% reduction in target lesions and an 87% drop in CA-125, from 362 U/mL to 47 U/mL. The tumor carries a PPP2R1A mutation, and the patient has only experienced Grade 1 treatment-emergent side effects and remains on therapy. Across the study, 22 patients have been treated at doses from 10 mg to 220 mg, and a further trial update is planned for the second quarter of 2026.
Nantahala Capital Management and its principals report a 4.50% beneficial stake in Aprea Therapeutics, Inc. common stock as of December 31, 2025. They collectively report beneficial ownership of 411,520 shares, including 205,760 shares that can be acquired within sixty days through exercise of warrants.
Nantahala, Wilmot B. Harkey, and Daniel Mack report zero sole voting or dispositive power and shared voting and dispositive power over all 411,520 shares. They state the holdings are owned in the ordinary course of business and are not intended to change or influence control of Aprea Therapeutics.
Aprea Therapeutics’ President and CEO Gilad Oren, who is also a director, reported buying 28,100 shares of common stock in a private placement that closed on January 30, 2026 at $0.89 per share. After this purchase, he directly holds 373,720 common shares, with additional indirect holdings of 1,200 shares by his daughter and 600 shares by his son.
Oren also received 28,100 common warrants with an exercise price of $0.765 per share, immediately exercisable but subject to limits so his ownership generally cannot exceed 4.99% of outstanding common stock or 9.99% of combined voting power. These warrants expire on the second anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144 on a cashless basis.
Aprea Therapeutics’ Senior Vice President and CFO John P. Hamill bought 5,700 shares of common stock in a private placement on January 30, 2026 at $0.89 per share, bringing his direct holdings to 33,433 shares.
He also received common warrants to purchase up to 5,700 additional shares at an exercise price of $0.765 per share. The warrants are immediately exercisable but include caps so his and his affiliates’ beneficial ownership cannot exceed 4.99% of common stock or 9.99% of total voting power after exercise. The warrants expire on the second anniversary of the earlier of the effectiveness of a registration statement for the underlying shares or the date those shares become eligible for sale under Rule 144, assuming cashless exercise.
Aprea Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 6,288,857 shares of common stock or pre-funded warrants, together with common stock warrants to purchase up to 6,288,857 shares. The combined effective offering price per share or pre-funded warrant plus accompanying warrant is $0.89, for expected aggregate gross proceeds of approximately $5.6 million.
The common warrants have a $0.765 exercise price, a two-year term starting after resale registration effectiveness or Rule 144 eligibility, and 4.99% or 9.99% ownership caps, with cashless exercise allowed in certain cases. Aprea agreed to file and maintain a resale registration statement and accepted issuance and variable-rate financing restrictions for defined periods. Maxim Group LLC will receive a 7% cash fee on gross proceeds and reimbursement of up to $35,000 in expenses. The company also reported a first unconfirmed partial response in its ongoing Phase 1 ACESOT-1051 study and updated its corporate presentation.
Aprea Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 6,288,857 shares of common stock or pre-funded warrants, together with common stock warrants to purchase up to 6,288,857 shares. The combined effective offering price per share or pre-funded warrant plus accompanying warrant is $0.89, for expected aggregate gross proceeds of approximately $5.6 million.
The common warrants have a $0.765 exercise price, a two-year term starting after resale registration effectiveness or Rule 144 eligibility, and 4.99% or 9.99% ownership caps, with cashless exercise allowed in certain cases. Aprea agreed to file and maintain a resale registration statement and accepted issuance and variable-rate financing restrictions for defined periods. Maxim Group LLC will receive a 7% cash fee on gross proceeds and reimbursement of up to $35,000 in expenses. The company also reported a first unconfirmed partial response in its ongoing Phase 1 ACESOT-1051 study and updated its corporate presentation.